Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC)Tricia R. Cottrell, Janis M. Taube, Amy S. Duffield et al.|Annals of Oncology|2018Cited by 588
K‐ <i>ras</i> oncogene activation in lung adenocarcinomas from former smokers evidence that K‐ <i>ras</i> mutations are an early and irreversible event in the development of adenocarcinoma of the lungWilliam H. Westra, Ralph H. Hruban, Robbert J.C. Slebos et al.|Cancer|1993Cited by 205